In this article, we will list the 5 Best Debt Free Stocks to Buy Right Now. Please visit 8 Best Debt Free Stocks to Buy Right Now if you would like to see the extended list and the methodology behind it.
5. Globus Medical, Inc. (NYSE:GMED)
On March 18, 2026, Wells Fargo assumed coverage of Globus Medical, Inc. (NYSE:GMED) with an Overweight rating and a $104 price target, while maintaining its rating, price target, and estimates.
Last month, Globus Medical, Inc. (NYSE:GMED) reported fourth-quarter EPS of $1.28, above the 96c consensus estimate, with revenue of $826.4M compared to the $803.29M consensus. Chief Executive Officer Keith Pfeil said momentum “accelerated in the fourth quarter,” pointing to double-digit sales and earnings growth and expansion across the company’s portfolio, including its spine business, supported by disciplined execution. Pfeil added that the company is focused on sustaining growth through product launches, expanding its sales force, and improving outcomes through its surgical ecosystem.
Globus Medical, Inc. (NYSE:GMED) raised its FY26 EPS outlook to $4.40-$4.50 from $4.30-$4.40, above the $4.24 consensus, and expects FY26 revenue of $3.18B-$3.22B compared to the $3.16B consensus.
Globus Medical, Inc. (NYSE:GMED) develops and commercializes healthcare solutions for musculoskeletal disorders globally.
4. SentinelOne, Inc. (NYSE:S)
On March 24, 2026, SentinelOne, Inc. (NYSE:S) announced the appointment of Barry Padgett as President and Chief Operating Officer, effective immediately. Barry Padgett previously served as Chief Growth Officer and, most recently, as interim Chief Financial Officer, with the transition coinciding with Sonalee Parekh formally assuming the role of Chief Financial Officer.
On March 23, 2026, SentinelOne, Inc. (NYSE:S) introduced a new lineup of AI security offerings covering both securing AI systems and using AI to automate security operations. The company said the products build on its existing AI security portfolio, including capabilities to secure autonomous agents and conduct “agentic investigations” with a single click. Among the offerings, Prompt AI Agent Security provides real-time visibility, monitoring, and policy enforcement for AI agents, while Prompt AI Red Teaming enables organizations to simulate attacks and test AI applications. SentinelOne also highlighted new capabilities within its Purple AI system, including “one-click Auto Investigation,” which automates threat analysis and response while maintaining analyst oversight.
On March 12, 2026, SentinelOne, Inc. (NYSE:S) reported Q4 adjusted EPS of 7c, above the 6c consensus estimate, with revenue of $271.2M compared to the $271.16M consensus. CEO Tomer Weingarten said the company “surpassed the $1 billion revenue milestone,” pointing to 22% year-over-year growth and full-year operating profitability, and added that customers are standardizing on its platform to secure AI and autonomous cybersecurity.
SentinelOne, Inc. (NYSE:S) provides cybersecurity solutions through its AI-powered platform for threat prevention, detection, and response.
3. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
On March 24, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi (SNY) announced that Japan’s Ministry of Health, Labour and Welfare approved Dupixent for the treatment of adults with moderate-to-severe bullous pemphigoid. The approval is based on data from the LIBERTY-BP-ADEPT Phase 2/3 trial evaluating Dupixent in adults with the condition.
On March 19, 2026, Wells Fargo raised the price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $825 from $800 and maintained an Equal Weight rating. Wells Fargo said new drugs and mechanisms such as CD20, BAFF/APRILs, and next generation complement inhibitors could expand the generalized Myasthenia Gravis market to $15B in the U.S. and $20B globally by 2036, more than tripling its size, and noted that Vertex Pharmaceuticals (VRTX), Amgen (AMGN), and Regeneron could be among the largest beneficiaries, with potential upside to current estimates.
Earlier in March, Barclays initiated coverage on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) with an Overweight rating and a $923 price target, saying the stock is “fundamentally mispricing” profits from Dupixent and highlighting pipeline opportunities, including Lynozyfic, along with indication expansion as an “underappreciated tailwind.”
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) develops and commercializes medicines across multiple therapeutic areas worldwide.
2. MongoDB, Inc. (NASDAQ:MDB)
On March 24, 2026, MongoDB, Inc. (NASDAQ:MDB) appointed Ryan Mac Ban as Chief Revenue Officer, effective April 27. Ryan Mac Ban brings more than 20 years of experience, most recently serving as Chief Revenue Officer at Confluent, and previously holding senior roles at UiPath, VMware, and Cisco. Outgoing CRO Paul Capombassis will support the transition through Q2.
On March 23, 2026, Mizuho analyst Siti Panigrahi upgraded MongoDB, Inc. (NASDAQ:MDB) to Outperform from Neutral with a price target of $325, up from $290, citing a “compelling” setup following fiscal Q4 results. Siti Panigrahi said the company’s growth profile “has inflected meaningfully,” pointing to fiscal 2026 net customer additions rising 60% year over year, net revenue retention improving from 118% to 121%, and headcount growing just 1% against 23% revenue growth, which signals a shift toward “efficient, durable growth.” Mizuho also highlighted AI as a “structural tailwind,” noting increased application creation and database demand, and views the fiscal 2027 outlook as conservative.
On March 16, 2026, Morgan Stanley lowered its price target on MongoDB, Inc. (NASDAQ:MDB) to $335 from $440 and maintained an Overweight rating, keeping revenue estimates largely unchanged while assuming more gradual margin expansion and applying a lower valuation multiple.
MongoDB, Inc. (NASDAQ:MDB) provides a general-purpose database platform through cloud-based, enterprise, and community offerings.
1. Okta, Inc. (NASDAQ:OKTA)
On March 19, 2026, Macquarie initiated coverage of Okta, Inc. (NASDAQ:OKTA) with an Outperform rating and a $100 price target. Macquarie said the company has “several levers to reaccelerate” remaining performance obligations and revenue growth, pointing to longer-term contracts, go-to-market changes introduced at the start of fiscal 2026, increased engagement with channel partners, and expansion through the AWS Marketplace. The firm also noted potential upside from agentic AI adoption in the identity space and said the shares trade at a discount to cybersecurity peers.
On March 16, 2026, Jefferies maintained a Buy rating and a $105 price target on Okta, Inc. (NASDAQ:OKTA) after attending its Okta Showcase 2026 event. Jefferies said identity is becoming more important in an “agentic world,” viewing Okta as a beneficiary, and highlighted tailwinds, go-to-market improvements, and what it described as conservative consensus estimates at 3.5 times expected forward revenue.
Earlier in March, Okta, Inc. (NASDAQ:OKTA) reported Q4 EPS of 90c, above the 85c consensus estimate, with revenue of $761M compared to the $749.5M consensus. CEO Todd McKinnon said performance was driven by “continued trust” from large organizations and adoption of new products, reinforcing the company’s identity platform, and added that AI is “redefining the future of software,” increasing the need to secure AI agents, which aligns with Okta’s platform capabilities.
Okta, Inc. (NASDAQ:OKTA) provides identity and access management solutions for organizations globally.
While we acknowledge the potential of OKTA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than OKTA and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 10 Must-Buy Real Estate Stocks to Invest In and 11 Best High Volume Penny Stocks to Buy Now.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
